Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14122
Abstract: e14122 Background: Our objective was to evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate end points for overall survival (OS) among patients with advanced non-small-cell lung cancer (NSCLC) in randomized trials of… read more here.
Keywords: end points; surrogate end; trials immunotherapy; pfs ... See more keywords